MVASI
Google image searchProduct monograph
Active ingredient
bevacizumab, 25 MG/ML
DIN: 02470756
Dosage form(s): SOLUTION
Route(s) of administration: INTRAVENOUS
Description: 400 MG/16 ML.SINGLE-USE VIAL.
Schedule: Prescription / Schedule D
Company: AMGEN CANADA INC
Date: 01-AUG-2019
ATC:
- L01 — ANTINEOPLASTIC AGENTS (ATC, ATC/DDD, )
- L01F — MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES (ATC, ATC/DDD)
- L01FG — VEGF/VEGFR (Vascular Endothelial Growth Factor) inhibitors (ATC, ATC/DDD)
- L01FG01 — BEVACIZUMAB (ATC/DDD)
Reference brand drug: Abevmy, Avastin, Aybintio, Bambevi, Mvasi, Vegzelma, Zirabev
